First Human Rejuvenation Trial Starts Soon, But Experts Split

Look, I've been tracking AI and biotech long enough to know when something's about to shift. And right now, the anti-aging crowd is buzzing harder than I've seen in years.

Here's what's happening: researchers are finally moving from lab mice to actual humans with their first legitimate rejuvenation trial. The timeline? "Shortly," according to sources close to the project. Yeah, I know that's vague, but in science-speak that usually means weeks, not months.

The timing couldn't be more interesting. Just last week at Davos, Elon Musk dropped his two cents on aging, calling it "very solvable" and predicting the answer will be embarrassingly obvious once we crack it. Classic Musk confidence, right? But here's the thing - he's not alone. Harvard professors and biotech startups are all converging on this idea that aging isn't some mystical process we can't touch.

What strikes me about this upcoming trial is how divided the experts are. Half think we're about to witness history. The other half? They're rolling their eyes so hard I can hear it through my screen. One researcher told me off the record that "rejuvenation" is a loaded word - what they're really testing is whether certain cellular markers can be nudged backward. Not exactly the fountain of youth, but hey, you gotta start somewhere.

I'll be honest - I'm cautiously optimistic. We've seen too many "breakthrough" aging studies fizzle out. But the fact that they're confident enough to test on humans? That's different. That means someone with deep pockets looked at the mouse data and said "yeah, let's do this." And in biotech, that kind of confidence usually means something.